A Business at a Glance
0 of 5 daily views used (5 remaining). Sign up free for 10 daily views, or try AAPL for a full preview.
PHARMANUTRA operates in the Drug Manufacturers - Specialty & Generic industry, Healthcare sector. Full business description from SEC filing not yet available.
| Metric | TTM | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 |
|---|---|---|---|---|---|---|
| Revenue | 115M | 115M | 100M | 83M | 68M | 56M |
| Net Income | 17M | 17M | 13M | - | - | - |
| EPS | $1.73 | $1.73 | $1.33 | $1,560.00 | $1,420.00 | $1,450.00 |
| Free Cash Flow | 0 | - | -1.2M | -8.7M | 15M | 10M |
| ROIC | 40.7% | 33.6% | 34.1% | 47.8% | 61.9% | 49.0% |
| Gross Margin | - | - | - | - | - | - |
| Debt/Equity | 0.00 | 0.45 | 0.56 | 0.46 | 0.21 | 0.08 |
| Dividends/Share | $0.00 | $0.85 | $0.80 | $1,560.00 | - | - |
| Operating Income | 31M | 31M | 26M | 24M | 20M | 16M |
| Operating Margin | 26.9% | 26.9% | 26.4% | 29.4% | 29.5% | 27.6% |
| ROE | 26.7% | 28.4% | 24.4% | - | - | - |
| Shares Outstanding | 0M | - | - | - | - | - |
| Metric | 2020 | 2021 | 2022 | 2023 | 2024 | TTM |
|---|---|---|---|---|---|---|
| Income Statement | ||||||
| Revenue | 56M | 68M | 83M | 100M | 115M | 115M |
| Gross Margin | N/A | N/A | N/A | N/A | N/A | N/A |
| R&D | N/A | N/A | N/A | N/A | N/A | N/A |
| SG&A | N/A | N/A | N/A | N/A | N/A | N/A |
| EBIT | 16M | 20M | 24M | 26M | 31M | 31M |
| Op. Margin | 27.6% | 29.5% | 29.4% | 26.4% | 26.9% | 26.9% |
| Net Income | N/A | N/A | N/A | 13M | 17M | 17M |
| Net Margin | N/A | N/A | N/A | 12.8% | 14.3% | 14.3% |
| Non-Recurring | 0 | 0 | 0 | 0 | 0 | 0 |
| Returns on Capital | ||||||
| ROIC | 49.0% | 61.9% | 47.8% | 34.1% | 33.6% | 40.7% |
| ROE | N/A | N/A | N/A | 24.4% | 28.4% | 26.7% |
| ROA | N/A | N/A | N/A | 12.1% | 14.4% | 14.1% |
| Cash Flow | ||||||
| Op. Cash Flow | 12M | 20M | 17M | 12M | 0 | 0 |
| Free Cash Flow | 10M | 15M | -8.7M | -1.2M | N/A | 0 |
| Owner Earnings | 9.5M | 19M | 16M | 9.0M | -3.9M | -3.9M |
| CapEx | 1.7M | 5.0M | 26M | 13M | 4.3M | 4.3M |
| Maint. CapEx | 2.3M | 1.4M | 1.3M | 3.1M | 3.9M | 3.9M |
| Growth CapEx | 0 | 3.6M | 25M | 10M | 322K | 322K |
| D&A | 2.3M | 1.4M | 1.3M | 3.1M | 3.9M | 3.9M |
| CapEx/OCF | 14.3% | 24.4% | 149.8% | 109.6% | N/A | 0.0% |
| Capital Allocation | ||||||
| Dividends Paid | 4.5M | 6.5M | 6.9M | 7.7M | 8.2M | 8.2M |
| Dividend Yield | N/A | N/A | N/A | N/A | N/A | N/A |
| Share Buybacks | 0 | 0 | 0 | 0 | 0 | 0 |
| Buyback Yield | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% |
| Stock-Based Comp | N/A | N/A | N/A | N/A | N/A | N/A |
| Debt Repayment | 0 | 0 | 0 | 0 | 0 | 0 |
| Balance Sheet | ||||||
| Net Debt | -14M | -20M | 1.4M | 11M | 12M | -16M |
| Cash & Equiv. | 16M | 29M | 22M | 19M | 16M | 16M |
| Long-Term Debt | N/A | N/A | N/A | N/A | N/A | N/A |
| Debt/Equity | 0.08 | 0.21 | 0.46 | 0.56 | 0.45 | 0.00 |
| Interest Coverage | 250.9 | 489.8 | 162.4 | 26.4 | 19.1 | 19.1 |
| Equity | 38M | 45M | 51M | 54M | 62M | 62M |
| Total Assets | 52M | 71M | 100M | 112M | 117M | 117M |
| Total Liabilities | 14M | 26M | 49M | 58M | 55M | 55M |
| Intangibles | N/A | N/A | N/A | 23M | 23M | 23M |
| Retained Earnings | N/A | N/A | N/A | N/A | N/A | N/A |
| Working Capital | 29M | 39M | 33M | 31M | 38M | 38M |
| Current Assets | 40M | 56M | 59M | 59M | 65M | 65M |
| Current Liabilities | 11M | 17M | 26M | 28M | 27M | 27M |
| Per Share Data | ||||||
| EPS | 1,450.00 | 1,420.00 | 1,560.00 | 1.33 | 1.73 | 1.73 |
| Owner EPS | N/A | N/A | N/A | N/A | N/A | N/A |
| Book Value | N/A | N/A | N/A | N/A | N/A | 0.00 |
| Cash Flow/Share | N/A | N/A | N/A | N/A | N/A | 0.00 |
| Dividends/Share | N/A | N/A | 1,560.00 | 0.80 | 0.85 | 0.00 |
| Shares Out. | N/A | N/A | N/A | N/A | N/A | 0.0M |
| Valuation | ||||||
| P/E Ratio | 0.0 | 0.1 | 0.0 | 42.4 | 31.3 | 45.6 |
| P/FCF | N/A | N/A | N/A | N/A | N/A | N/A |
| EV/EBIT | -0.9 | -1.0 | 0.1 | 0.4 | 0.4 | -0.5 |
| Price/Book | N/A | N/A | N/A | N/A | N/A | N/A |
| Price/Sales | N/A | N/A | N/A | N/A | N/A | N/A |
| FCF Yield | N/A | N/A | N/A | N/A | N/A | N/A |
| Market Cap | 0 | 0 | 0 | 0 | 0 | 0 |
| Avg. Price | 24.93 | 50.76 | 64.69 | 56.37 | 54.09 | 78.90 |
| Year-End Price | 37.30 | 71.60 | 62.00 | 56.40 | 54.20 | 78.90 |
PHARMANUTRA passes 3 of 9 quality checks, indicating weak fundamentals.
The company's 5-year average ROIC is 45.3%. Total shareholder yield (dividends) is 1.1%.
PHARMANUTRA (PHN-MI) has a 5-year average return on invested capital (ROIC) of 45.3%. This indicates strong capital allocation and a potential competitive advantage.
Yes, PHARMANUTRA (PHN-MI) pays a dividend with a trailing twelve-month yield of 1.08%.
PHARMANUTRA (PHN-MI) operates in the Drug Manufacturers - Specialty & Generic industry, within the Healthcare sector.
PHARMANUTRA (PHN-MI) reported annual revenue of $115 million in its most recent fiscal year, based on SEC EDGAR filings.
PHARMANUTRA (PHN-MI) has a net profit margin of 14.3%. This is a healthy margin.
PHARMANUTRA (PHN-MI) has a debt-to-equity ratio of 0.45. This indicates a conservatively financed balance sheet.
PHARMANUTRA (PHN-MI) reported earnings per share (EPS) of $1.73 in its most recent fiscal year.
PHARMANUTRA (PHN-MI) has a return on equity (ROE) of 28.4%. This indicates the company generates strong returns for shareholders.
The Ledger Terminal provides 5 years of financial data for PHARMANUTRA (PHN-MI), sourced directly from SEC EDGAR filings. This includes income statements, balance sheets, cash flow statements, and key financial ratios.
No recent items.